203179-00-4

Basic information

• Product Name: Benzamide, 3-bromo-4-chloro-N-methoxy-N-methyl-
• Synonyms: 3-bromo-4-chloro-N-methoxy-N-methylbenzamide
• CAS NO: 203179-00-4
• Molecular Formula: C9H9BrClNO2
• Molecular Weight: 278.533
• Mol File: 203179-00-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 400.1±35.0 °C(Predicted)
• Density: 1.554±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Benzamide, 3-bromo-4-chloro-N-methoxy-N-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, 3-bromo-4-chloro-N-methoxy-N-methyl-(203179-00-4)
• EPA Substance Registry System: Benzamide, 3-bromo-4-chloro-N-methoxy-N-methyl-(203179-00-4)

Safety Data

• Hazardous Substances Data: 203179-00-4(Hazardous Substances Data)

Upstream product

• 42860-10-6 3-bromo-4-chlorobenzoic acid 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 

Downstream Products

• 54826-14-1 1-(3-bromo-4-chlorophenyl)ethan-1-one 
• 1373939-92-4 3-(3-(5-aminopyrazin-2-yl)-4-chlorophenyl)-5,5-dimethylisoxazol-4(5H)-one 
• 1373938-91-0 N-(5-(2-chloro-5-(5,5-dimethyl-4-oxo-4,5-dihydroisoxazol-3-yl)-phenyl)pyrazin-2-yl)-2,6-difluorobenzamide 
• 1201662-80-7 3,5-dichloro-N-((4',6-dichlorobiphenyl-3-yl)methyl)-N-(4-fluorobenzyl)-2-hydroxybenzenesulfonamide 
• 1201663-94-6 1-(4',6-dichlorobiphenyl-3-yl)-N-(4-fluorobenzyl)methanamine 
• 86265-88-5 3-bromo-4-chloro-benzaldehyde 

Relevant articles and documents

Discovery of a Novel Potent and Selective Calcium Release-Activated Calcium Channel Inhibitor: 2,6-Difluoro- N-(2′-methyl-3′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1′-biphenyl]-4-yl)benzamide. Structure-Activity Relationship and Preclinical Characterization

The role of calcium release-activated calcium (CRAC) channels is well characterized and is of particular importance in T-cell function. CRAC channels are involved in the pathogenesis of several autoimmune diseases, making it an attractive therapeutic target for treating inflammatory diseases, like rheumatoid arthritis (RA). A systematic structure-activity relationship study with the goal of optimizing lipophilicity successfully yielded two lead compounds, 36 and 37. Both compounds showed decent potency and selectivity and a remarkable pharmacokinetic profile. Further characterization in in vivo RA models and subsequent histopathological evaluation of tissues led to the identification of 36 as a clinical candidate. Compound 36 displayed an excellent safety profile and had a sufficient safety margin to qualify it for use in human testing. Oral administration of 36 in Phase 1 clinical study in healthy volunteers established favorable safety, tolerability, and good target engagement as measured by levels of IL-2 and TNF-α.

HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS

The present invention provides compound of Formula (I): or a stereoisomer, tautomer, salt or solvate thereof, wherein the variables are defined herein. The compounds of formula (I) are inhibitors of Bcl-2 family antiapoptotic proteins, compositions containing the compounds and methods of treating diseases using the compounds.

Calcium receptor modulating agents

The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.